Cas:659-18-7 Tris(2,2,2-trifluoroethyl) borate manufacturer & supplier

Chemical Name:Tris(2,2,2-trifluoroethyl) borate

CAS.NO:659-18-7

Synonyms:Tris(2,2,2-trifluoroethyl) borate

Molecular Formula:C₆H₆BF₉O₃

Molecular Weight:307.907

HS Code:2920909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:94.3±40.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.293

PSA:27.69000

Exact Mass:308.026642

LogP:5.36

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Tris(2,2,2-trifluoroethyl) borate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tris(2,2,2-trifluoroethyl) borate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tris(2,2,2-trifluoroethyl) borate Use and application,Tris(2,2,2-trifluoroethyl) borate technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. Tris(2,2,2-trifluoroethyl) borate manufacturer Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. Tris(2,2,2-trifluoroethyl) borate supplier ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� Tris(2,2,2-trifluoroethyl) borate vendor Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. Tris(2,2,2-trifluoroethyl) borate factory ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.��